FDA Approves GSK's Arexvy Vaccine for Adults Aged 50-59

FDA Approves GSK's Arexvy Vaccine for Adults Aged 50-59

Anna Petrovna
1 min read

FDA Approves GSK's Arexvy Vaccine for High-Risk Adults Aged 50-59

The FDA has expanded its approval of GSK's respiratory syncytial virus (RSV) vaccine, Arexvy, to include high-risk adults aged 50 to 59, marking the first FDA-approved vaccine for this age group. This development is set to address a significant health gap and is expected to have a substantial impact on public health.

Key Takeaways

  • FDA expands approval of GSK's Arexvy vaccine to include high-risk adults aged 50-59 for severe RSV.
  • Arexvy becomes the first FDA-approved vaccine for this age group, previously only approved for ages 60 and above.
  • Approximately 13 million high-risk Americans in the 50-59 age range could benefit from this expanded approval.
  • GSK's vaccine has demonstrated strong efficacy in late-stage trials for high-risk adults with underlying conditions.
  • GSK projects that Arexvy could achieve peak annual sales exceeding £3 billion.


The expanded approval of GSK's Arexvy vaccine is expected to strengthen the company's position in the RSV vaccine sector, potentially leading to peak annual sales of over £3 billion. This significant development not only addresses a crucial public health need but also has the potential to drive innovation and competition within the market. Additionally, it may signal a shift in the FDA's approach to vaccine approvals with a focus on age-specific risk groups.

Did You Know?

  • Respiratory Syncytial Virus (RSV): A common respiratory virus that can cause severe illness, particularly in infants, older adults, and individuals with compromised immune systems or chronic health conditions.
  • GSK (GlaxoSmithKline): A leading multinational pharmaceutical and biotechnology company headquartered in London, UK, known for its extensive portfolio of vaccines, medications, and consumer healthcare products.
  • Peak Annual Sales: Refers to the highest projected yearly revenue a product is expected to achieve during its market life cycle. GSK anticipates that its Arexvy vaccine could reach over £3 billion in annual sales at its peak, illustrating substantial market demand and potential profitability.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings